Presepsin blood test for early sepsis detection in severe burn patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

About 270 adults with severe burns (≥20% total body surface area) admitted to a burn ICU will be enrolled and have blood taken at predefined time points. Researchers will measure presepsin levels and compare them with C-reactive protein, procalcitonin, Sepsis-3 clinical criteria, and blood culture results. The primary outcome is presepsin's sensitivity and specificity for diagnosing sepsis in this high-risk population. The observational design aims to determine whether presepsin offers earlier or more accurate sepsis detection than standard markers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged ≥ 18 years admitted to Hangang Sacred Heart Hospital Burn ICU with total body surface area (TBSA) ≥ 20 %
* Clinical suspicion of sepsis prompting blood culture and biomarker sampling
* Ability to understand the study and provide written informed consent (or via legally authorized representative)

Exclusion Criteria:

* Inability to undergo research blood draw due to emergent surgery or major trauma at sampling time
* Chronic immunosuppressive conditions (e.g., long-term high-dose steroids, organ transplant, congenital immunodeficiency)
* Pregnant women or those with significant psychiatric conditions precluding consent
* Any other medical or safety concerns deemed inappropriate by the investigator

Where it's running

• Hangang Sacred Heart Hospital, Hallym University Medical Center
  Seoul, Seoul, South Korea Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early detection of sepsis-related blood clotting problems in severe burn patients

  This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.

  Recruiting Center for Traumatology and Major Burns, Ben Arous · Tunis · NCT07914205

• Comparing Interleukin 6 and Procalcitonin for Sepsis Detection in Burn Patients

  This study is testing whether measuring Interleukin-6 can help doctors find sepsis in burn patients better than the usual test with procalcitonin.

  Recruiting Ain Shams University · Cairo · NCT06915974

• Registry for monitoring CytoSorb device use in critically ill patients

  This study is collecting information on how the CytoSorb device helps critically ill patients to improve care for conditions like septic shock and acute respiratory distress syndrome.

  Recruiting at 24 sites CytoSorbents, Inc · Klagenfurt and 27 other locations · NCT05146336

• Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care

  This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07922213

• Neutrophil EMR3 as a biomarker for sepsis in ICU patients

  Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07896018

• Thymalfasin added to standard care for adults with sepsis and immune dysfunction

  This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07866118

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.